Please try another search
(Reuters) - The U.S. Food and Drug Administration approved Zevra Therapeutics' drug for a rare and fatal genetic disorder, the first treatment to get a nod for the condition, the health regulator...
On Friday, H.C. Wainwright maintained a positive outlook on Cytokinetics (NASDAQ:CYTK) shares, reiterating a Buy rating and a $90.00 price target. The firm's optimism is rooted in the potential of...
CELEBRATION, Fla. - Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, announced today the FDA approval of MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC)....
Investing in cheap undervalued stocks priced under $10 can offer potential growth without the need for significant capital. Using the Investing.com 'Under $10/Share' stock screener, I searched for...
Faster treatment opens marketTheraclion (PA:ALTHER) has announced interim clinical results on a crucial innovation, Beamotion, to speed up EchoPulse therapy five times. The CE-marked EchoPulse device...
If Fluence Corporation Ltd (AX:FLC) can deliver on its H218e target, its shares could re-rate sharply. Its membrane-aerated biofilm reactor (MABR) technology provides a competitive advantage in the...
Instrument Type
Region
Sector
Industry
Date
Category
Provider